vs
Krystal Biotech, Inc.（KRYS）与Revolution Medicines, Inc.（RVMD）财务数据对比。点击上方公司名可切换其他公司
Krystal Biotech, Inc.自由现金流更多（$75.4M vs $-139.5M）。过去两年Krystal Biotech, Inc.的营收复合增速更高（53.8% vs -100.0%）
Krystal Biotech是一家处于临床阶段的生物技术企业，专注于研发和商业化针对罕见重症皮肤病的新型基因疗法，主要面向北美和欧洲市场，服务缺乏有效常规治疗方案的单基因皮肤病患者。
Tempus AI是美国健康科技企业，2015年由埃里克·莱夫科夫斯基在伊利诺伊州芝加哥创立，成立契机为其妻子确诊乳腺癌。公司依托数据与人工智能技术，为肿瘤、心脏病、放射医学、抑郁症等领域提供包含诊断在内的精准医疗服务，2024年6月14日于纳斯达克上市，股票代码为TEM。
KRYS vs RVMD — 直观对比
营收规模更大
KRYS
是对方的Infinity倍
$0
自由现金流更多
KRYS
多$214.9M
$-139.5M
两年增速更快
KRYS
近两年复合增速
-100.0%
损益表 — Q4 2025 vs Q4 2024
| 指标 | | |
|---|---|---|
| 营收 | $107.1M | $0 |
| 净利润 | $51.4M | $-194.6M |
| 毛利率 | — | — |
| 营业利润率 | 41.5% | — |
| 净利率 | 48.0% | — |
| 营收同比 | 17.5% | — |
| 净利润同比 | 13.0% | -20.4% |
| 每股收益（稀释后） | $1.69 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KRYSRVMD
| Q4 25 | $107.1M | — | ||
| Q3 25 | $97.8M | — | ||
| Q2 25 | $96.0M | — | ||
| Q1 25 | $88.2M | — | ||
| Q4 24 | $91.1M | $0 | ||
| Q3 24 | $83.8M | $0 | ||
| Q2 24 | $70.3M | $0 | ||
| Q1 24 | $45.3M | $0 |
净利润KRYSRVMD
| Q4 25 | $51.4M | — | ||
| Q3 25 | $79.4M | — | ||
| Q2 25 | $38.3M | — | ||
| Q1 25 | $35.7M | — | ||
| Q4 24 | $45.5M | $-194.6M | ||
| Q3 24 | $27.2M | $-156.3M | ||
| Q2 24 | $15.6M | $-133.2M | ||
| Q1 24 | $932.0K | $-116.0M |
营业利润率KRYSRVMD
| Q4 25 | 41.5% | — | ||
| Q3 25 | 42.3% | — | ||
| Q2 25 | 40.9% | — | ||
| Q1 25 | 41.0% | — | ||
| Q4 24 | 45.4% | — | ||
| Q3 24 | 26.8% | — | ||
| Q2 24 | 12.2% | — | ||
| Q1 24 | -14.8% | — |
净利率KRYSRVMD
| Q4 25 | 48.0% | — | ||
| Q3 25 | 81.2% | — | ||
| Q2 25 | 39.9% | — | ||
| Q1 25 | 40.5% | — | ||
| Q4 24 | 49.9% | — | ||
| Q3 24 | 32.4% | — | ||
| Q2 24 | 22.2% | — | ||
| Q1 24 | 2.1% | — |
每股收益（稀释后）KRYSRVMD
| Q4 25 | $1.69 | — | ||
| Q3 25 | $2.66 | — | ||
| Q2 25 | $1.29 | — | ||
| Q1 25 | $1.20 | — | ||
| Q4 24 | $1.53 | $-1.13 | ||
| Q3 24 | $0.91 | $-0.94 | ||
| Q2 24 | $0.53 | $-0.81 | ||
| Q1 24 | $0.03 | $-0.70 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $496.3M | $2.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $2.3B |
| 总资产 | $1.3B | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资KRYSRVMD
| Q4 25 | $496.3M | — | ||
| Q3 25 | $392.6M | — | ||
| Q2 25 | $353.8M | — | ||
| Q1 25 | $308.8M | — | ||
| Q4 24 | $344.9M | $2.3B | ||
| Q3 24 | $374.0M | $1.5B | ||
| Q2 24 | $345.8M | $1.6B | ||
| Q1 24 | $359.0M | $1.7B |
股东权益KRYSRVMD
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $984.7M | — | ||
| Q4 24 | $946.4M | $2.3B | ||
| Q3 24 | $885.8M | $1.6B | ||
| Q2 24 | $838.9M | $1.6B | ||
| Q1 24 | $799.2M | $1.7B |
总资产KRYSRVMD
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | $2.6B | ||
| Q3 24 | $982.3M | $1.8B | ||
| Q2 24 | $917.7M | $1.8B | ||
| Q1 24 | $853.3M | $1.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $77.5M | $-138.3M |
| 自由现金流经营现金流 - 资本支出 | $75.4M | $-139.5M |
| 自由现金流率自由现金流/营收 | 70.4% | — |
| 资本支出强度资本支出/营收 | 2.0% | — |
| 现金转化率经营现金流/净利润 | 1.51× | — |
| 过去12个月自由现金流最近4个季度 | $188.9M | $-567.7M |
8季度趋势，按日历期对齐
经营现金流KRYSRVMD
| Q4 25 | $77.5M | — | ||
| Q3 25 | $39.7M | — | ||
| Q2 25 | $52.7M | — | ||
| Q1 25 | $31.0M | — | ||
| Q4 24 | $52.8M | $-138.3M | ||
| Q3 24 | $58.9M | $-130.4M | ||
| Q2 24 | $-4.2M | $-128.2M | ||
| Q1 24 | $15.9M | $-160.6M |
自由现金流KRYSRVMD
| Q4 25 | $75.4M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $50.8M | — | ||
| Q1 25 | $24.8M | — | ||
| Q4 24 | $52.0M | $-139.5M | ||
| Q3 24 | $57.8M | $-133.9M | ||
| Q2 24 | $-5.3M | $-130.6M | ||
| Q1 24 | $14.6M | $-163.7M |
自由现金流率KRYSRVMD
| Q4 25 | 70.4% | — | ||
| Q3 25 | 38.8% | — | ||
| Q2 25 | 52.9% | — | ||
| Q1 25 | 28.1% | — | ||
| Q4 24 | 57.1% | — | ||
| Q3 24 | 69.0% | — | ||
| Q2 24 | -7.5% | — | ||
| Q1 24 | 32.3% | — |
资本支出强度KRYSRVMD
| Q4 25 | 2.0% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 7.0% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 1.6% | — | ||
| Q1 24 | 2.8% | — |
现金转化率KRYSRVMD
| Q4 25 | 1.51× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 1.38× | — | ||
| Q1 25 | 0.87× | — | ||
| Q4 24 | 1.16× | — | ||
| Q3 24 | 2.17× | — | ||
| Q2 24 | -0.27× | — | ||
| Q1 24 | 17.05× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
